Vis enkel innførsel

dc.contributor.authorIngulfsvann Hagen, Bjørn
dc.contributor.authorLerdal, Anners
dc.contributor.authorSøraas, Arne Vasli
dc.contributor.authorLandrø, Nils Inge
dc.contributor.authorBø, Ragnhild
dc.contributor.authorSmåstuen, Milada Cvancarova
dc.contributor.authorBecker, Jaqueline
dc.contributor.authorStubberud, Jan Egil
dc.date.accessioned2022-12-09T11:41:50Z
dc.date.available2022-12-09T11:41:50Z
dc.date.issued2022-10-05
dc.description.abstractBackground: Post-COVID-19 condition is frequently comprised of persistent cognitive sequela, including deficits in attention and executive functions (EFs), which can act as a barrier for regaining pre-illness functional levels. Goal Management Training (GMT) is a cognitive rehabilitation (CR) intervention for improving attention and EFs that has received empirical support in studies of other patient groups. The present study aims to determine the efficacy of GMT for improving everyday attention and EFs in adults who experience persistent cognitive deficits after COVID-19.<p> <p>Methods: This study protocol describes an open-label randomized controlled trial comparing the efficacy of GMT to a wait list control condition (WL), for improving persistent (> 2 months) cognitive sequela in post-COVID-19 condition. The study aims to recruit 240 participants aged 18 to 65 years with a history of SARS-CoV-2 infection and perceived attentional and EF difficulties in daily life. Participants will be block randomized (computer-algorithm) to either group-based GMT (n = 120) or WL (n = 120). GMT will be internet-delivered to groups of six participants in six two-hour sessions delivered once a week. The primary outcome will be the Metacognition Index of the Behavior Rating Inventory of Executive Function – Adult Version, a self-report measure assessing everyday EF difficulties, specifically metacognition, at six months post-treatment. Secondary outcomes include performance-based neurocognitive measures, and tertiary outcomes include rating scales of cognition, emotional health, quality of life, and fatigue. <p>Conclusion: Study findings could contribute to providing an evidence-based treatment option for symptoms that are frequent and debilitating following a prevalent condition.en_US
dc.identifier.citationIngulfsvann Hagen BOI, Lerdal AL, Søraas AVL, Landrø NI, Bø R, Småstuen MC, Becker J, Stubberud J. Cognitive rehabilitation in post-COVID-19 condition: A study protocol for a randomized controlled trial. Contemporary Clinical Trials. 2022;122en_US
dc.identifier.cristinIDFRIDAID 2061109
dc.identifier.doi10.1016/j.cct.2022.106955
dc.identifier.issn1551-7144
dc.identifier.issn1559-2030
dc.identifier.urihttps://hdl.handle.net/10037/27758
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalContemporary Clinical Trials
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleCognitive rehabilitation in post-COVID-19 condition: A study protocol for a randomized controlled trialen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution 4.0 International (CC BY 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution 4.0 International (CC BY 4.0)